Our core provides CFAR laboratory researchers with access to cutting-edge and novel molecular profiling technologies experiments, including high-throughput sequencing of host or pathogen DNA or RNA, mass spectrometry assays of proteins or metabolites, or experiments that integrate many of these data types together. The diversity of molecular profiling technologies and research questions that can lead from them often require idiosyncratic domain-specific expertise in order to design experiments and then to process and interpret the resulting data. These skills alone or together are rarely found in a single CFAR researcher laboratory funded by traditional sources. The MPCB core will allow CFAR researchers to circumvent these and other barriers, allowing them to undertake new and innovative research directions. A priority of the MPCB core will be to support new investigators, whether they are young investigators or established researchers who are newly using profiling technologies in their research, especially those who are developing preliminary work for independent funding.
Aim 1 : To provide services for experimental design, data processing, and data interpretation for experiments that profile human cells and tissues, viruses, and/or microbiome communities.
Aim 2 : To develop and disseminate new high-impact HIV relevant computational capabilities to CFAR investigators.
Aim 3 : To disseminate expertise into the CFAR community through formal classroom training. Our core services, faculty, staff and leadership model are new, and represents an evolution of a previous core in response to new opportunities and needs among laboratory-based HIV/Aids researchers.
|LaCourse, Sylvia M; Deya, Ruth W; Graham, Susan M et al. (2017) Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 76:74-81|
|Coban, Hamza; Robertson, Kevin; Smurzynski, Marlene et al. (2017) Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen. AIDS 31:1565-1571|
|Goyette, Marielle S; Wilson, Kate S; Deya, Ruth et al. (2017) Brief Report: Association Between Menopause and Unprotected Sex in High-Risk HIV-Positive Women in Mombasa, Kenya. J Acquir Immune Defic Syndr 74:488-492|
|Dombrowski, Julia C; Bove, Joanna; Roscoe, James C et al. (2017) ""Out of Care"" HIV Case Investigations: A Collaborative Analysis Across 6 States in the Northwest US. J Acquir Immune Defic Syndr 74 Suppl 2:S81-S87|
|Dross, Sandra E; Munson, Paul V; Kim, Se Eun et al. (2017) Kinetics of Myeloid-Derived Suppressor Cell Frequency and Function during Simian Immunodeficiency Virus Infection, Combination Antiretroviral Therapy, and Treatment Interruption. J Immunol 198:757-766|
|Drozd, Daniel R; Saag, Michael S; Westfall, Andrew O et al. (2017) Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice. Medicine (Baltimore) 96:e6275|
|Koelle, David M; Norberg, Peter; Fitzgibbon, Matthew P et al. (2017) Worldwide circulation of HSV-2?×?HSV-1 recombinant strains. Sci Rep 7:44084|
|Mugwanya, Kenneth K; John-Stewart, Grace; Baeten, Jared (2017) Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. Expert Opin Drug Saf 16:867-871|
|Puttkammer, Nancy; Domerçant, Jean Wysler; Adler, Michelle et al. (2017) ART attrition and risk factors among Option B+ patients in Haiti: A retrospective cohort study. PLoS One 12:e0173123|
|Donnell, Deborah; Ramos, Eric; Celum, Connie et al. (2017) The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. AIDS 31:2007-2016|
Showing the most recent 10 out of 1172 publications